BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Short (1M)
Edelweiss Recommends 'Hold' On Thyrocare
According to Edelweiss, the Return on Capital Employed (RoCE) of Thyrocare's pathology business and asset turnover look relatively good, but lowest among listed players. Thyrocare has been aggressively expanding its infrastructure on the back of a 68 per cent uptick in authorised service providers, of which more than 80 per cent are online clients, the brokerage adds.